AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9809500
Drug: Azelastine hydrochloride
RxNorm normalized name: Azelastine Hydrochloride
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelastine hydrochloride nasal spray (280 microg twice daily)
Trial: 7695326
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.5 mg/kg of body weight per day)
Trial: 28804009
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein drink (30 g/120 kcal, 140 mL) consumed 3 hours before a buffet meal
Trial: 28804009
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein drink (30 g/120 kcal, 140 mL) consumed 2 hours before a buffet meal
Trial: 28804009
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein drink (30 g/120 kcal, 140 mL) consumed 1 hour before a buffet meal
Trial: 28804009
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein drink (30 g/120 kcal, 140 mL) consumed immediately before a buffet meal
Trial: 15321026
Drug: Latanoprost once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost once-weekly
Trial: 15321026
Drug: Latanoprost once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost once-daily (control)
Trial: 12575552
Drug: Lingjiao Jiangya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lingjiao Jiangya Pill
Trial: 8162926
Drug: Dexamethasone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.1 mg)
Trial: 31179316
Drug: Not practicing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not practicing at least 30 min daily walks
Trial: 23683134
Drug: Allopurinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (200 mg or 300 mg)
Trial: 17997711
Drug: Strontium ranelate
RxNorm normalized name: Strontium ranelate
DrugBank: Strontium ranelate (DB09267)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Strontium ranelate 2 g/d orally for 3 years
Trial: 8900554
Drug: Misoprostol in
RxNorm normalized name: Product containing misoprostol in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol in patients requiring concomitant antacid use
Trial: 1800188
Drug: Celandin-aloevera-psyllium preparation
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celandin-aloevera-psyllium preparation
Trial: 31971679
Drug: Teprotumumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for subsequent infusions, administered intravenously every 3 weeks for 21 weeks)
Trial: 26847728
Drug: D-glucose (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-glucose (10 mmol L(-1))
Trial: 22431338
Drug: Riluzole treatment
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole treatment for 1 week
Trial: 20094001
Drug: weblink to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: weblink to CDC sexually transmitted disease treatment guidelines
Trial: 15595937
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) therapy after placebo delay
Trial: 10588611
Drug: Inhaled allergen
RxNorm normalized name: Inhaled allergen mix specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled allergen challenge
Trial: 10588611
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids pretreatment
Trial: 2108408
Drug: L-649,923 (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-649,923 (oral LTD4 antagonist)
Trial: 6765920
Drug: Timolol (10-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (10-30 mg twice daily)
Trial: 28403379
Drug: Resveratrol 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 125 mg/d
Trial: 28403379
Drug: Resveratrol 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 500 mg/d
Trial: 26044566
Drug: probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: probucol 500 mg/day
Trial: 26044566
Drug: aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 100 mg/day
Trial: 16781624
Drug: Engystol-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engystol-based therapy
Trial: 16781624
Drug: Conventional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapies (antihistamines, antitussives, NSAIDs)
Trial: 10722768
Drug: Ipratropium 40
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium 40 microg four times daily
Trial: 27983686
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg polyphenols derived from red wine and grape extracts in protein-rich beverages (dairy, soy)
Trial: 27983686
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg polyphenols derived from red wine and grape extracts in protein-free beverage
Trial: 27983686
Drug: Placebo (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (six gelatine capsules)
Trial: 18285548
Drug: Maribavir 400
RxNorm normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maribavir 400 mg once daily
Trial: 15624040
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg/day (n = 30)
Trial: 29153754
Drug: Combined activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined activity program (90-minute sessions weekly for 40 weeks)
Trial: 21876572
Drug: 0.5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml/kg of 0.25 % bupivacaine with 1 mg/kg of tramadol (Group B)
Trial: 21876572
Drug: 0.5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml/kg of 0.25 % bupivacaine (Group A)
Trial: 16731091
Drug: Infected black
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infected black women who received CDC recommended treatment
Trial: 11049909
Drug: Atropine 5
RxNorm normalized name: Isopto Homatropine 5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 5 microg/kg (small-dose)
Trial: 11049909
Drug: Atropine 10
RxNorm normalized name: Isopto Atropine 10 MG/ML Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 10 microg/kg (large-dose)
Trial: 8615503
Drug: Tizanidine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tizanidine 12 mg
Trial: 1397667
Drug: Vivida (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vivida (500 mg/day for 90 days)
Trial: 1397667
Drug: Imedeen (380
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imedeen (380 mg/day for 90 days)
Trial: 26996246
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS up-titration from 30 mg to 60 mg
Trial: 26996246
Drug: Valsartan up-titration
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan up-titration from 80 mg to 160 mg
Trial: 26996246
Drug: Low-dose combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose combination of Nifedipine GITS (30 mg) and Valsartan (80 mg)
Trial: 26996246
Drug: Low-dose monotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose monotherapy of Nifedipine GITS (30 mg)
Trial: 26996246
Drug: Low-dose monotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose monotherapy of Valsartan (80 mg)
Trial: 25275672
Drug: Topiramate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100 mg, oral, twice daily, titrated over 2 weeks)
Trial: 22527079
Drug: Levosimendan (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (0.1 μg/kg/min continuous infusion for 72 hours)
Trial: 22527079
Drug: Standard post‐CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard post‐CPB inotrope infusion
Trial: 10373872
Drug: Questionnaire administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Questionnaire administered on the second postnatal day
Trial: 2201759
Drug: Subgingival irrigation
RxNorm normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival irrigation with 0.12% CHX and daily marginal irrigation with 0.04% CHX
Trial: 2201759
Drug: Subgingival irrigation
RxNorm normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival irrigation with 0.12% CHX and daily marginal irrigation with water
Trial: 2201759
Drug: Subgingival and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgingival and daily marginal irrigation with water
Trial: 31713774
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (Se) treatment at 50 to 200 nmol/L
Trial: 31713774
Drug: LPS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS treatment (only LPS)
Trial: 31713774
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (Se) treatment with LPS (LS50 to LS200)
Trial: 31713774
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (Se) treatment at 50 to 100 nmol/L
Trial: 30231899
Drug: Selenium (Se)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (Se) treatment
Trial: 28407007
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily (Arm A)
Trial: 28407007
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, each twice daily) plus polaprezinc 150 mg twice daily (Arm B)
Trial: 28407007
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy alone (Arm C)
Trial: 28407007
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B (Triple therapy plus polaprezinc 150 mg)
Trial: 26286610
Drug: 0.1% Mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% Mometasone Furoate Cream (MF) in combination with LA-Cer moisturizer
Trial: 26286610
Drug: 0.1% Mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% Mometasone Furoate Cream (MF)
Trial: 11094038
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of prostacyclin in 15 patients with PPH and 3 with sPAH.
Trial: 8659199
Drug: Celiprolol 200
RxNorm normalized name: celiprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol 200 mg/day
Trial: 1644341
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen supplementation (2 l/min)
Trial: 6240785
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G (4.8 X 10(6) units im) plus probenecid (1 g perorally)
Trial: 6240785
Drug: Spectinomycin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin (2 g im)
Trial: 26813849
Drug: 60 once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 once-daily pills after each donation (19 mg of iron)
Trial: 26813849
Drug: 60 once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 once-daily pills after each donation (38 mg of iron)
Trial: 25664051
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D oral supplementation (45000 IU/week for 2 months and a single 45000 IU in the last month)
Trial: 18410902
Drug: Intravenous busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous busulfan 130 mg/m(2) once daily x 4 days and fludarabine 40 mg/m(2) daily x 4 days
Trial: 12429757
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Sequential transection of the triangular fibrocartilage complex and the interosseous membrane
Trial: 12429757
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Sequential transection of the interosseous membrane and the triangular fibrocartilage complex
Trial: 10339471
Drug: Prophylactic inhalations
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic inhalations with aerosolized amphotericin B (aeroAmB) at a dose of 10 mg twice daily
Trial: 10339471
Drug: No inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No inhalation prophylaxis
Trial: 7499945
Drug: Beclomethasone nasal
RxNorm normalized name: beclomethasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone nasal spray (Beconase) applied to one nostril for six weeks
Trial: 1959515
Drug: Dutch dietary
RxNorm normalized name: ditch stonecroft extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutch dietary guidelines diet (G)
Trial: 31099485
Drug: MTX therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX therapy
Trial: 31099485
Drug: MTX cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX cumulative dose
Trial: 31099485
Drug: MTX treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX treatment duration
Trial: 25431865
Drug: L-DNR/FLAG (liposomal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DNR/FLAG (liposomal daunorubicin, fludarabine, cytarabine, G-CSF)
Trial: 25431865
Drug: L-DNR/FLAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DNR/FLAG
Trial: 15676064
Drug: Full vacuum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full vacuum suction drainage (pressure = 700 g/m2)
Trial: 15676064
Drug: Half vacuum
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half vacuum suction drainage (pressure = 350 g/m2)
Trial: 6986242
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets twice daily)
Trial: 30793177
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 3 (250,000 IU single dose followed by 50,000 IU every other week)
Trial: 30793177
Drug: Placebo (identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identically matched placebo pill)
Trial: 26159020
Drug: CHSQABC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHSQABC + routine Western medicine treatment (Xinyue Capsule: 2 pills, 3 times/day; Compound Chuanxiong Capsule: 2 pills, 3 times/day for half a year)
Trial: 26159020
Drug: Routine Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Western medicine treatment (control group)
Trial: 26159020
Drug: CHSQABC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHSQABC + routine Western medicine treatment
Trial: 20415263
Drug: Cycloferon (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloferon (exact dosage not specified)
Trial: 6356326
Drug: Gastrointestinal hormones
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastrointestinal hormones (VIP, motilin, enteroglucagon)
Trial: 31727580
Drug: Algorithm-guided empirical
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm-guided empirical tuberculosis treatment
Trial: 25273547
Drug: Lactobacillus paracasei
RxNorm normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus paracasei subsp. paracasei L. casei W8® (1010 cfu daily) for four weeks
Trial: 23783097
Drug: CDCA (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA (5 mmol/L)
Trial: 23783097
Drug: CDCA (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA (15 mmol/L)
Trial: 23783097
Drug: CDCA (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA (5 or 15 mmol/L)
Trial: 23783097
Drug: Sodium oleate
RxNorm normalized name: sodium oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium oleate with 5 mmol/L CDCA
Trial: 19173181
Drug: (90)Y‐DOTATATE (7.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y‐DOTATATE (7.4 GBq/m(2) cumulative dose)
Trial: 19173181
Drug: (90)Y‐ibritumomab tiuxetan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y‐ibritumomab tiuxetan (1200 MBq max dose)
Trial: 9372504
Drug: Triple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dose (TD) gadolinium (0.3 mmol/kg)
Trial: 9372504
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (s.d.) gadolinium (0.1 mmol/kg)
Trial: 29559344
Drug: Ustekinumab treatment
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab treatment
Trial: 27475688
Drug: Oral ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketorolac 10 mg plus intramuscular placebo (1 mL saline solution)
Trial: 27475688
Drug: Intramuscular tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular tramadol 50 mg diluted in 1 mL saline solution plus oral placebo (similar tablet to oral ketorolac)
Trial: 24047817
Drug: Tetravalent vaccine
RxNorm normalized name: DENGUE TETRAVALENT VACCINE,LIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent vaccine and placebo
Trial: 24047817
Drug: A/H5N1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/H5N1 vaccine and placebo
Trial: 24047817
Drug: A/H5N1 and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/H5N1 and seasonal vaccines
Trial: 23368891
Drug: Conventional cannulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cannulation (CC)
Trial: 23368891
Drug: Accidental guidewire
RxNorm normalized name: Anacardium occidentale whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accidental guidewire insertions and unintended injections of contrast into the main pancreatic duct
Trial: 18793563
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional oral agents alone)
Trial: 1586733
Drug: Prophylactic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic heparin 100 U/kg/d by continuous infusion from day -8 until day +30 post-BMT
Trial: 1586733
Drug: Prophylactic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic heparin after allogeneic BMT
Trial: 3032827
Drug: Dietary fibre
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fibre tablets
Trial: 29447076
Drug: Pork collagen
RxNorm normalized name: Pork Collagen
DrugBank: Pork collagen (DB14100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pork collagen peptide (CP) 2.5 g/day
Trial: 29447076
Drug: Placebo 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2.5 g/day
Trial: 20003398
Drug: Cognitive activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive activity intervention consisting of ten 90-minute sessions delivered twice per week over a period of five weeks.
Trial: 17312091
Drug: SS-QOL observable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SS-QOL observable scales (e.g., activities)
Trial: 15334426
Drug: Lumiracoxib 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 50 mg twice daily
Trial: 15334426
Drug: Lumiracoxib 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib 200 mg twice daily
Trial: 2735156
Drug: Waiting-for-treatment control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-for-treatment control group
Trial: 28211216
Drug: eplerenone 50
RxNorm normalized name: eplerenone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eplerenone 50 mg
Trial: 24063830
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus atorvastatin 10 mg (Period I)
Trial: 24063830
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus atorvastatin 20 mg (Period II)